UK pharma uses Irish subsidiary to tap EU for Covid research funding

The Irish subsidiary of a British pharmaceutical firm is to lead a major research project aimed at developing a new treatment for Covid-19 patients.

Exvastat, a Cambridge-based, clinical-stage pharmaceutical company established in 2016, has secured €3.6m in EU and industry funding to test the application of an existing drug for use in people infected with the coronavirus.